The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.

about

The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer.

Item

http://www.wikidata.org/entity/Q50347388

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@en

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@nl

type

Item

label

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@en

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@nl

prefLabel

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@en

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@nl

P1476

The Impact of Treatment Prefer ...... tive Metastatic Breast Cancer.

@en

P2093

Hirofumi Mukai

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Isaka

http://www.w3.org/2001/XMLSchema#string

Kenichi Watanabe

http://www.w3.org/2001/XMLSchema#string

Kentaro Imi

http://www.w3.org/2001/XMLSchema#string

SELECT BC Study Group

http://www.w3.org/2001/XMLSchema#string

Yasuhiro Hagiwara

http://www.w3.org/2001/XMLSchema#string

Yutaka Matsuyama

http://www.w3.org/2001/XMLSchema#string

P2860

Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

Is breast cancer survival improving?

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.

Comparison of dynamic treatment regimes via inverse probability weighting.

In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin.

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.

In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

The Potential for Postrandomization Confounding in Randomized Clinical Trials.

P304

315-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000479033

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28848126

http://www.w3.org/2001/XMLSchema#string

P932

5804827

http://www.w3.org/2001/XMLSchema#string